ConductScience.org, home

Library / Trial comparisons

Fluarix Tetra vs mRNA-1010: Number of Participants With Unsolicited AEs

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.2460.2310.261wilsonClinicalTrials.gov
Risk in group 20.2640.2480.28wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.0179-0.03970.00404newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 20.9320.8551.02logClinicalTrials.gov
Odds ratio, group 1 over group 20.910.8111.02logClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Fluarix Tetra than on mRNA-101056from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Fluarix TetraParticipants received a single dose of Fluarix Tetra by IM injection on Day 1.7493,048OG000ClinicalTrials.gov
Group 2mRNA-1010Participants received a single dose of mRNA-1010 by IM injection on Day 1.8003,035OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypePRIMARYClinicalTrials.gov
TitleNumber of Participants With Unsolicited AEsClinicalTrials.gov
Description
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure.
ClinicalTrials.gov
Time frameUp to 28 days post-vaccinationClinicalTrials.gov
PopulationThe Safety Set included all participants who were randomized and received any study vaccination.ClinicalTrials.gov

Trial 8

FieldValueSource
TitleA Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsClinicalTrials.gov
NCT numberNCT05415462ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsSeasonal InfluenzaClinicalTrials.gov
InterventionsmRNA-1010, Fluarix TetraClinicalTrials.gov
Lead sponsorModernaTX, Inc.ClinicalTrials.gov
Results first posted2024-09-24ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT05415462?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.